05:50 , Jun 2, 2018 |  BioCentury  |  Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
19:55 , Apr 27, 2018 |  BC Week In Review  |  Company News

Lysogene and others partner to develop gene therapy for Fragile X

Lysogene S.A. (Euronext:LYS), SATT Conectus Alsace (Illkirch, France) and Institute of Genetics and Molecular and Cellular Biology (IGBMC) (Illkirch, France) partnered to develop a gene therapy to treat fragile X. SATT Conectus said it provided...
23:28 , Dec 4, 2017 |  BC Extra  |  Company News

Mustang, Harvard partner on CRISPR CAR T therapies

Mustang Bio Inc. (NASDAQ:MBIO) partnered with Harvard University to develop CRISPR-Cas9-enhanced CAR T therapies targeting hematologic and solid tumor cancers. The biotech in-licensed CRISPR-Cas9 gene editing technology from Harvard, as well as technology related to...
19:10 , May 16, 2017 |  BC Extra  |  Clinical News

New technologies in focus at ASGCT

ToolGen Inc. (KONEX:199800), Editas Medicine Inc. (NASDAQ:EDIT) and Selecta Biosciences Inc. (NASDAQ:SELB) each spotlighted new technologies and techniques at the American Society for Gene and Cell Therapy (ASGCT) meeting in Washington, D.C. ToolGen Inc. showed...
08:00 , Mar 3, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Diacylglycerol kinase α (DGKα); SH2 domain containing 1A (SH2D1A); T cell receptor (TCR)

Cancer INDICATION: Cancer Patient sample and mouse studies suggest inhibiting DGKα could help treat X-linked lymphoproliferative disorder (XLP-1). The disorder is caused by mutations in SH2D1A , a negative regulator of DGKα, that impair TCR...
07:00 , Oct 10, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Pulmonary disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Cystic fibrosis (CF) Diacylglycerol kinase-i (DGKI); epithelial sodium channel (ENaC) In vitro and cell culture studies suggest DGKI inhibition could help treat CF. An...
07:00 , May 17, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Huntington's disease (HD) Diacylglycerol kinase-e (DGKE) Mouse, fly and cell culture studies suggest inhibiting DGKE could help treat HD. In mouse...
08:00 , Feb 28, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Type 2 diabetes Diacylglycerol kinase-d (DAG kinase-d) Studies in mice, rats and human skeletal muscle suggest that enhancing DAG kinase-d...